















































Lecture Goal 4 – Prepare a handout and other visual aids that are appropriate for pharmacy students.

Lecture Goal 5 – Use active learning techniques to engage students at a higher level in the classroom.

Lecture Goal 6 - Work with the course coordinator/primary instructor to schedule the class and verify that the lecture content is adequate.

Lecture Goal 7 – Write clear and appropriate test questions for the class material presented. (Questions should be submitted with the lecture material for review by the course coordinator and Teaching Certificate Coach as appropriate prior to the presentation of the lecture material in class.)

#### 4. Deadlines:

Seminar: A **seminar** topic and Content Advisor must be selected by mid-August. Objectives, pre-work, and rough draft of slides for the seminar are due **21 days** prior to the first presentation in the series to the RPD, Presentations Coordinator and the Content Advisor. Feedback will be returned to the resident within 5 business days. A final handout and completed draft of slides will be due **14 days** prior to the first seminar in the series to the RPD and Content Advisor.

ACPE-Approved Presentation: A topic and Content Advisor must be selected for the **CE presentation** by the end of July (fall series) or November (spring series). Objectives and other paperwork required for accreditation of the ACPE presentation are due a full **75 days** prior to the first day of the presentation series to the USHP CE Administrator and to the resident's chosen CE Content Advisor. A first draft of all materials for the ACPE-approved presentation (including handout and slides) are due *without fail* to the RPD, Presentations Coordinator and the Content Advisor **65 days** prior to the beginning of the CE series (approximately: PGY2-Aug 31; PGY1-January 7). The resident shall then make improvements based on feedback from the advisor and provide a second draft **45 days** prior to the presentation series to the individuals listed above and to the USHP CE Coordinator. These deadlines must be met to fulfill program requirements. Residents who fail to meet their deadlines will be required to present their seminar or CE in a closed-door session with the RPD and Content Advisor and risk losing CE-accreditation for their presentation.

Recitations/Lectures: The recitation/lecture dates and due dates for materials and test questions will be negotiated with the Course Coordinator. When the lecture topics are selected, the resident must immediately notify the RPD and Presentation Coordinator.

Project Platform Presentation: Mountain States practice sessions will be held starting 3-4 weeks prior to the meeting in order to meet slide submission deadlines. Each resident will practice presenting at least twice to Research Committee members and

project advisors.

5. At the end of each presentation, the resident will identify to the audience who his/her advisor is and thank him/her for his/her effort. CE mentors must sign the conflict of interest statement for USHP in addition to the resident completing their contract.
6. Audience members will complete a standard evaluation for the continuing education presentation and seminar. Failure to achieve satisfactory evaluations, meet the ACPE requirements, or meet deadlines will result in the seminar or continuing education presentation being revised and repeated by the resident. The resident will not receive a certificate of residency completion until all presentation requirements are met.
7. Shortly after the seminar (within 1 week following presentation), the resident and either the RPD or the Content Advisor should meet and discuss how the resident performed, what the resident thought went well and did not go well, how the resident thinks he/she can improve for next time, and any comments on the evaluations that need further discussion.
8. The residents shall attend all seminar and CE sessions, practice sessions, and project presentations as assigned by program and approved by the rotation preceptor. In the event of conflicts with rotation requirements, the resident shall resolve the conflict with the preceptor of the rotation and the RPD. PGY1 residents shall attend a minimum of 3 of their resident colleagues' seminars and 3 CE presentations.
9. Presentation handouts, slides, evaluations, and test questions (if appropriate) shall be included in the Resident's electronic portfolio for all four required presentations.

## SEMINAR EVALUATION FORM

**DATE:** \_\_\_\_\_  
**EVALUATOR:** \_\_\_\_\_  
**PRESENTER:** \_\_\_\_\_  
**TITLE:** \_\_\_\_\_

**This is a learning experience for both you and the resident. Please provide constructive feedback. “Great Job!” is not constructive feedback.**

**Evaluation codes: S = Satisfactory NI = Needs Improvement**

Please provide constructive feedback to resident, especially if “NI” is checked

### I. PRESENTATION STYLE

The style was conducive to my learning.

| Objective                      | S | NI | Comments |
|--------------------------------|---|----|----------|
| Voice Projection               |   |    |          |
| Pace                           |   |    |          |
| Lack of Distracting Mannerisms |   |    |          |
| Professional Dress             |   |    |          |
| Eye Contact                    |   |    |          |

Additional Comments:

### II. VISUAL AIDS

The material and techniques used enhanced my comprehension and interest.

| Objective  | S | NI | Comments |
|--|---|----|----------|
| Use of equipment and lighting  |   |    |          |
| Reasonable amount of slides utilized for the allotted time                                   |   |    |          |
| The slides/ handouts enhanced the topic (e.g., through the use of diagrams, figures, tables) |   |    |          |
| The number of words per slide allowed easy comprehension for the audience                    |   |    |          |

Additional Comments:

### III. PREPARATION

The presenter was prepared regarding the clinical implications of the topic presented.

| Objective   | S | NI | Comments |
|---|---|----|----------|
| Did you feel the presenter achieved an expert level of knowledge such that information presented was valid? |   |    |          |

Additional Comments:



#### IV. EFFECTIVENESS OF PRESENTATION

The resident was able to identify the clinical dilemma, orient the audience to where these data fit in clinical practice, present data from the literature to answer the clinical question, and then clearly provide guidance to audience members on what to do clinically if faced with this dilemma.

| Objective  | S | NI | Comments   |
|--|---|----|--|
| Was the clinical dilemma presented clearly at the beginning of the seminar?  |   |    |  |
| Were the objectives clear, relevant and reflect the content presented?   |   |    |  |
| Were the objectives effectively addressed by the end of the seminar?   |   |    |  |
| Was the resident able to appropriately orient the audience as to where this clinical controversy fits in contemporary clinical practice? |   |    |  |
| Did the resident effectively use published literature to support/refute what is currently done in contemporary clinical practice?        |   |    |  |
| Was the resident able to focus the presentation into clear, concise "take-home" points that were easily understood by the audience?      |   |    |  |
| Were the conclusions reached by the resident credible based on the published data provided?  |   |    |  |
| Were clear recommendations made regarding what the audience member should do if confronted with this clinical scenario in the future?    |   |    | (If these were not given, a recommendation to suggest redoing the seminar is strongly recommended) |
| Did the resident enhance your understanding of this clinical dilemma?  |   |    |  |

Additional Comments:

#### V. OVERALL IMPRESSION OF PRESENTER

It is encouraged that ALL attendees provide comments to these questions so that the residents may improve.

| Objective  | Please provide constructive comments to each question? |
|--|--|
| How effective was the resident at presenting a seminar that was clear, concise, well-structured, and well-supported by literature? |  |
| What steps do you suggest this presenter take to improve their ability to give an effective seminar?                               |  |

Additional Comments:

\_\_\_ Pass \_\_\_ Recommend rework and second presentation

**Seminar Pre-Work: Complete this form for each study used to prepare your seminar – submit to Seminar Advisor**  
 Questionnaire for Evaluating Primary Literature compiled by Linda S. Tyler, PharmD  
 Article:

| Introduction  | yes/ no/ partial        | Comments   |
|---|-------------------------|--|
| Is the reason for conducting the study discussed?   |                         |  |
| Are the study objectives clearly defined?   |                         |  |
| Is the null hypothesis clear?   |                         |  |
| <b>Methodology</b>  | <b>yes/ no/ partial</b> | <b>How might this influence the results or affect the validity of the study?</b> |
| <b>Have adequate measures been taken to prevent selection bias?</b>   |                         |  |
| • Is the study population adequately defined?   |                         |  |
| • How were subjects selected? What are the inclusion criteria? Are the selection procedures clearly defined?  |                         |  |
| Case-control:<br>How were cases selected?<br>How were controls selected?<br>Are the controls comparable to the cases?<br>Was bias introduced in the selection process?                  |                         |  |
| Follow-up/cross-sectional:<br>How was the study population selected?<br>Was bias introduced in the selection process?   |                         |  |
| Experimental:<br>Were subjects randomly selected? Did all qualified subjects have an equal chance of being admitted to the study? Are the treatment groups comparable?                  |                         |  |
| • Are pertinent patient specific data provided? (ie healthy subjects vs patients, sex, age, concurrent disease states, concurrent therapy, race, weight or other pertinent information) |                         |  |
| <b>Have adequate measures been taken to prevent classification bias?</b>  |                         |  |
| • Does the study use specific definitions for the study parameters?   |                         |  |
| • How were patients classified for entrance into the study? Do they have the disease of interest? (case-control, experimental)  |                         |  |
| • Is the severity of disease described?   |                         |  |
| • How were the risk factors classified?   |                         |  |
| • How were the outcomes classified?   |                         |  |
| <b>Have adequate measures been taken to prevent confounding bias?</b>   |                         |  |
| • Have measures been taken to prevent competing interventions that may influence the results?   |                         |  |
| Are exclusion criteria clearly defined?   |                         |  |
| <b>Have adequate measures been taken to prevent information bias?</b>   |                         |  |
| • Are data sources used appropriate and likely to have the appropriate information? What is the quality of the data?  |                         |  |
| • Have the issues related to recall bias been adequately addressed?   |                         |  |
| <b>Have adequate measures been taken to prevent measurement bias?</b>   |                         |  |
| • What measures were used to evaluate the outcomes of the study? Are they adequately described?   |                         |  |
| • Were the measures used appropriate?   |                         |  |

|   |                     |          |
|---|---------------------|----------|
| • Were objective measures used?   |                     |          |
| • Are the measures reproducible?  |                     |          |
| <b>Were subjects observed for a sufficient length of time?</b>  |                     |          |
| <b>Have adequate measures been taken to prevent observer bias?</b>  |                     |          |
| • Are the observers specified?  |                     |          |
| • Have measures been taken to prevent inter-observer variation?   |                     |          |
| <b>Experimental studies:</b>  |                     |          |
| • Were subjects randomized? Are randomization procedures appropriate and clearly defined? [Allocation bias]                                 |                     |          |
| • Are the interventions well described?   |                     |          |
| • Is the study blinded? Are blinding procedures appropriate?  |                     |          |
| • Were specific data on drug regimens given including dose, dosage form, duration of administration, time of dose in relationship to meals? |                     |          |
| • Were all study drugs given in appropriate doses and regimens?   |                     |          |
| • Are both groups comparable, and treated in the same manner, except for the intervention?  |                     |          |
| • Were the measures adequate to insure or evaluate compliance?  |                     |          |
| • Were there any competing therapies that would have influenced the results   |                     |          |
| If the study is a crossover trial, was the washout period adequate between interventions?   |                     |          |
| <b>Statistical Analyses</b>   |                     |          |
| • Have the authors described the statistical analyses to be used in the study?  |                     |          |
| • Are the statistical tests appropriate for the type of data (nominal, ordinal, continuous)?  |                     |          |
| • Is the sample size determination information included?  |                     |          |
| • Have appropriate significance levels been established?  |                     |          |
| • Is the power of the study described?  |                     |          |
| <b>Based on the methodology, is the study likely to have external validity?</b>   |                     |          |
| • Is the study sample representative of the general population?   |                     |          |
| • Were the interventions practical? (experimental)  |                     |          |
| <b>Results</b>  | yes/ no/<br>partial | Comments |
| <b>Patients studied</b>   |                     |          |
| • Is the number of patients specified?  |                     |          |
| • Can all patients be accounted for?  |                     |          |
| • Is the number of dropouts given? Are the reasons for dropping out described? (experimental, follow-up)                                    |                     |          |
| • Were sufficient numbers of patients studied?  |                     |          |
| • Were patient demographics presented?  |                     |          |

|   |                  |          |
|---|------------------|----------|
| • Do the groups look similar based on demographics?   |                  |          |
| <b>Data presentation</b>  |                  |          |
| • Are data presented for all measurements specified in the methodology?   |                  |          |
| • Are data presented objectively?   |                  |          |
| <b>Statistical Analyses</b>   |                  |          |
| • Are appropriate descriptive statistics presented? [ie measure of central tendency (median, mean, mode), spread of the data (range), variation in the data (SD)] |                  |          |
| • Are p values and confidence intervals specified?  |                  |          |
| • Are the inferential statistical tests applied appropriately?  |                  |          |
| • Are statistical analyses meaningful?  |                  |          |
| <b>Discussion/ Conclusions</b>  | yes/ no/ partial | Comments |
| Are the author's conclusions appropriate based on the data presented?   |                  |          |
| Are the results statistically significant?  |                  |          |
| Are the results clinically significant?   |                  |          |
| Does the author discuss objectively the limitations to the study?   |                  |          |
| Are the conclusions consistent with the purpose of the study?   |                  |          |
| Can the conclusions be extrapolated to the population in general?   |                  |          |
| <b>Overall</b>  |                  |          |
| Do the title and abstract appropriately reflect the content of the study?   |                  |          |
| Does the author cite mostly primary literature? Is the article referenced appropriately?  |                  |          |
| Who sponsored the study?  |                  |          |
| What is the reputation of the journal? Is it peer reviewed?   |                  |          |
| Are there editorials available that discuss the article? (companion editorials or editorials that come out later)   |                  |          |

Summary: Overall assess the study's strengths and weaknesses

Does the study have internal validity?

Does the study have external validity? Is it relevant to your problem/situation/practice

PRESENTATION EVALUATION FORM FOR THE SPRING CE SERIES:

**SAMPLE: Speaker Evaluation**

University of Utah Resident CE Series

Resident Name Here  
"CE TITLE GOES HERE"

---

**1. Did the presenter meet the stated educational objectives? (Place Pharmacist Objectives 1<sup>st</sup>, then Tech Objectives 2<sup>nd</sup>, clearly delineating which is which.)**

- |                                   |     |    |
|-----------------------------------|-----|----|
| a. Objective #1 written out here. | Yes | No |
| b. Objective #2 written out here. | Yes | No |
| c. Objective #3 written out here. | Yes | No |
| d. Objective #4 written out here. | Yes | No |
| e. Objective #5 written out here. | Yes | No |

**Please rate the following, 1 = very dissatisfied, 5 = very satisfied**

2. How satisfied are you with this presentation? 1 2 3 4 5

3. Was the content of this presentation relevant to your area of practice? Yes No

4. How does this topic pertain to your educational goals? \_\_\_\_\_

---

5. The speaker was:

- |                                     |   |   |   |   |   |
|-------------------------------------|---|---|---|---|---|
| a. Interesting                      | 1 | 2 | 3 | 4 | 5 |
| b. Practical                        | 1 | 2 | 3 | 4 | 5 |
| c. Answered questions appropriately | 1 | 2 | 3 | 4 | 5 |
| d. Showed mastery of the subject    | 1 | 2 | 3 | 4 | 5 |

6. Please rate the quality of the learning materials. 1 2 3 4 5

7. Please rate the effectiveness of the learning activity. 1 2 3 4 5

8. The presentation was free from bias, promotion, or advertisement? Yes No

If no, please explain:

9. What other topics would you like to see presented in the future? \_\_\_\_\_

10. Please use the space below to provide any constructive comments about the presenter or the topic presented and if you had any unanswered questions.

## Mountain States Conference Platform Presentation Evaluation Form

Presenter's Name: \_\_\_\_\_ Abstract #: \_\_\_\_\_

Presenter's Institution: \_\_\_\_\_

Evaluator:  Resident     Fellow     Preceptor     RPD     Other: \_\_\_\_\_

| Presentation Feedback   | 1=Needs<br>Improvement<br>5=Excellent | Comments |
|---|---------------------------------------|----------|
| Presenter demonstrated strong presentation skills: pace and volume were appropriate. Good eye contact. Free of distracting mannerisms.                                  | 1 2 3 4 5                             |          |
| Slides were clear and readable and augmented the presentation well.   | 1 2 3 4 5                             |          |
| The presentation was organized and flowed well.   | 1 2 3 4 5                             |          |
| Project was clearly described: sufficient background to understand the project; methods clearly described; results presented for each objective; conclusions are clear. | 1 2 3 4 5                             |          |
| Presenter handled questions well.   | 1 2 3 4 5                             |          |
| Handout is well organized and contains useful information.  | 1 2 3 4 5                             |          |

**Presentation strengths:**

**One key way to improve presentation:**

| Project / Research Feedback   | 1=Needs<br>Improvement<br>5=Excellent | Comments |
|---|---------------------------------------|----------|
| Reasons for selecting project clear; objectives clearly stated.                               | 1 2 3 4 5                             |          |
| Methods appropriate to answer research question; statistics appropriate for the study design. | 1 2 3 4 5                             |          |
| Results relevant to pharmacy practice.  | 1 2 3 4 5                             |          |
| Conclusions match the results presented.  | 1 2 3 4 5                             |          |
| Resident's interest and participation in project evident.                                     | 1 2 3 4 5                             |          |

**Please provide additional comments that will help the presenter with future research.**

## Resident Participation in Conferences and Committees

1. Residents shall meet on a weekly basis for a 1 to 2 hour directed discussion session. Attendance at teaching certificate and leadership conferences is **mandatory** for PGY1 Residents. PGY1 residents must negotiate absences with the program director before the conference begins. All other residents are encouraged to attend to learn and to mentor the PGY1 residents as often as they are able.
2. A schedule of discussion topics shall be developed and a discussion leader shall be assigned. Possible conference topics include teaching and training, leadership, journal club, clinical topics, and time and project management, etc.
3. Residents shall be responsible to participate in or lead discussion and to be prepared by reading background materials and by supplementing with additional readings.
4. PGY1 residents on rotations located on campus are required to attend weekly Resident Conference on Wednesdays at 4:00 p.m. as assigned provided they are not on patient care rounds, or ambulatory care conference at 7AM at Redwood as assigned during ambulatory care rotations Residents must notify all preceptors that they are required to attend weekly resident conference prior to starting each rotation.
5. The resident shall attend all departmental staff meetings related to their area of practice. For University Hospital and Huntsman Hospital-based residents, staff meetings are held on the last Wednesday of the month at 2:00 p.m. unless otherwise directed.
6. Residents are encouraged to participate in department and hospital-based committees and task forces (e.g., Med Error Review Committee, policy task forces, Pharmacy Medication Safety Committee, RAC subcommittees, etc.) Residents wishing to attend a P&T meeting will work with Erin Fox to develop an item to present for P&T.
7. Residents are encouraged to participate on state and national committees and task forces (i.e., ASHP, Vizient, or USHP).
8. Residents are encouraged to attend RAC meetings as they are able. Meetings are the fourth Wednesday of each month at 3:00 p.m. Residents will be excused for topics involving potential disciplinary issues.

## **Conference Attendance**

### **ASHP Midyear Clinical Meeting - required**

Residents will be given educational leave to attend the meeting. Residents shall spend time helping recruit potential candidates for the next residency class, attend residency showcase, and attend the Utah reception. The residents will also attend CE presentations and will give summaries in writing or during Grand Rounds upon their return.

### **Mountain States Residents Conference – required for all residents**

The Mountain States Conference for Pharmacy Residents, Fellows and Preceptors will be held each May. Utah residents will present their project to other residents and preceptors during this meeting. Residents are expected to attend assigned presentations, and as many other resident presentations as possible as one of the host organizations.

### **Other Conferences**

PGY2 residents may have department funding for one additional specialty conference per year. Other conferences may be attended at the resident's own expense and using accrued vacation time (PTO-S), provided the time away from rotation does not prevent the resident from meeting the required rotation objectives. If the resident has a presentation or poster prepared with a pharmacist preceptor at University of Utah Health, they should complete two steps. First, verify with the RPD and the preceptor of the rotation affected by the conference that the absence is acceptable. Once permission is granted by the preceptor and RPD, complete the Travel Request Form available on the online Pharmacy Help Book and submit the request to their Pharmacy Director and a copy to the RPD. Educational leave and/or partial reimbursement for travel and registration may be available from the Pharmacy Department depending on available budget resources.

Professional conduct is expected from all attendees while representing the University of Utah at any conference. Unprofessional conduct during meetings may result in disciplinary action.



## Residency Program Portfolio

1. The resident shall maintain a Residency Portfolio electronically which shall be a complete record of the resident's program activities. Residents are to maintain the e-portfolio throughout the year. The e-portfolio shall be submitted to the RPD at the conclusion of the residency training program and shall be a requirement for successful completion of the program.
2. The residency program portfolio shall include the following items:
  - a. Completed Resident Self-Evaluation and Planning Form
  - b. Residency profile and plan
  - c. Documentation of activities, projects, presentations, and edited documents.
  - d. Evaluations of the preceptors, rotations, and self that are **NOT** posted on PharmAcademic
  - e. A record of all in-services, presentations, and seminars given
    1. Handouts developed
    2. A list of attendees/participants (as available)
    3. Evaluations
    4. Slides
  - f. Residency Project
    1. RAC and IRB proposals
    2. Grant/funding proposal
    3. Final manuscript
    4. Value Summary (as appropriate for each project)
    5. PHI should NOT be posted in the e-portfolio
  - g. A list of all seminars/meetings attended
    1. Staff meetings
    2. Committee meetings (including professional associations)
    3. Educational presentations (i.e., grand rounds)
    3. Departmental staff development/pharmacy grand rounds
    4. State/local continuing education
    5. Regional/national meetings
    7. Residency program retreat
  - h. A current curriculum vitae
  - i. Staffing/PTO/ECS log
3. An electronic file will be kept for each resident and will contain planning forms, presentations, and projects.

## Evaluation Guidelines

1. All evaluations shall be timely and documented on appropriate forms in PharmAcademic.
2. If for any reason an evaluation is not documented in PharmAcademic, copies of the completed evaluations shall be forwarded to the RPD and uploaded to the resident's PharmAcademic supplemental documents (eg, student evaluations of the resident.)
3. Evaluation of Resident:

The performance of the resident shall be based upon the use of predetermined goals and objectives derived from the ASHP Residency Program Design and Conduct: Goals and Objectives.

- a. Rotation: The resident shall be responsible to attend periodic meetings with their rotation preceptor to assess and evaluate their progress in the rotation. The frequency and scheduling of these sessions shall be determined by the rotation preceptor and the resident. At a minimum, an oral mid-rotation evaluation, a final self-evaluation (using the same evaluation form as the preceptor), and final evaluation by the preceptors will be performed.

If the rotation is team-taught, the preceptors will communicate with each other about the resident's progress, specific recommendations for improvement, and upcoming assignments and special requirements.

Within seven days after the completion of each rotation, and **preferably on the last day of the rotation**, the preceptor will evaluate the overall performance of the resident using the Summative Evaluation form in PharmAcademic. The evaluation will be reviewed with and signed by the resident, and forwarded to the RPD for co-signature in PharmAcademic.

- c. Quarterly: Quarterly evaluation sessions with the RPD shall be scheduled to assess progress toward meeting global goals and program requirements. The resident shall schedule the sessions to be held in approximately July (baseline), October, January, April and June. This information is documented as part of the Customized Development Plan (CTP).
- d. Failure to demonstrate adequate performance or to meet program deadlines may result in formal disciplinary action including possible dismissal from the residency program.
- e. The Achieved Definition for Residents: The RPD may allow some goals and objectives to be marked as achieved only after completion of specific activities. For

example, a resident is unlikely to achieve goals related to writing prior to successfully completing a RAC proposal or Drug Information rotation. The resident appropriately and consistently demonstrates during all learning opportunities, rotations, and throughout the year the following in knowledge, skills and attitudes (as appropriate for each goal evaluated):

Achieved Definition:

1. Competently and safely care for patients at a level acceptable for all pharmacists in the University system.
2. Present patients in a logical and succinct order and understand the priorities of pharmaceutical needs.
3. Serves as a valuable resource for the healthcare team.
4. Gives timely responses that are clear and appropriate for audience understanding.
5. Demonstrates an advanced level of problem solving skills. Demonstrating knowledge, and proper use, of all available resources.
6. Able to autonomously identify and prioritize current tasks as well as upcoming deadlines.
7. Appropriately balance time between work tasks, personal life, projects, and learning opportunities in order to complete all requirements, while continuing to increase knowledge and skills.
8. Through actions demonstrates reliability, responsibility, and trustworthiness on a level that would be desirable for employment.
9. Helps to create an amiable, productive work environment.

4. Evaluation of Preceptor and Learning Experience

Within seven days after the completion of each rotation, and **preferably by the last day of the rotation**, the resident shall complete the Preceptor and Learning Experience Evaluation. This evaluation shall be discussed with the preceptor and submitted to the RPD through PharmAcademic.

5. Evaluation of Program

Residents may bring program issues to the attention of the RPD, the Chief Pharmacy Officer, or to RAC at any time during the year.

Residency Program Retreat:

- a. The resident class (including PGY1 and PGY2 residents) shall be responsible to schedule two residency program retreats that shall be held in December and June. The residents, Chief Pharmacy Officer and the Chair of RAC shall attend the retreat.
- b. Residents shall develop an agenda for the retreat in cooperation with either

the CPO or Chair of RAC.

- c. The purpose of the retreat shall be to address the strengths and weaknesses of the programs.
  - d. The residents shall produce a summary of the proceedings of the retreat that shall include recommendations for change that are identified by the program participants.
6. The residency program considers a resident's evaluations as privileged information within the program to ensure focused development and feedback for each resident. Use of evaluations as a recruiting tool for future employers or residency/fellowship programs is discouraged. The RPD and preceptors will NOT release copies of a resident's evaluations to anyone NOT serving as a preceptor for the Program.

## **Appendix A**

### Job Description

**Department of Pharmacy Services  
University of Utah Hospitals and Clinics  
University of Utah Health Sciences Center**

Pharmacy Resident (7578)

**Fair Labor Standards Act (FLSA): Exempt**

**Revision Date: Mar 04, 2013**

Position Summary

This position provides all the functions of a clinical pharmacist as part of a 1-2 year structured training program to develop the resident's skills and knowledge. The residency program director sets the program requirements and is responsible for the overall training program. As part of this training program, the resident will complete a project. Residents are supervised by program preceptors for each of their assigned training rotations.

Essential Functions

- Performs all the essential functions of a Clinical Pharmacist.
  - Solves problems in the medication use process for patients and the organization.
  - Identifies and engages in organizational and department quality improvement activities to improve patient care, medication use process, and pharmacy operations.
  - Educates and trains residents, students, interns, colleagues and other health care professionals as well as supervises technicians, residents, interns, or trainees in their job tasks.
  - Responsible for the medication use process of preparing and dispensing medications following medication use policy and all laws, regulations, and standards applicable to pharmacy practice.
  - Assesses appropriate drug information and literature resources, and provides effective information to varied audiences including patients, other health care professions, and peers.
- Meets all the program requirements of a resident as outlined in the program requirements.
- Conducts a major project.

Knowledge / Skills / Abilities

- Ability to perform the essential functions of the job as outlined above.
- Ability and willingness to train department trainees (e.g. students, interns, and new staff).
- Ability to assess data regarding the patient's status and provide care as described in the department's policies and procedures manual.
- Demonstrated knowledge and skills necessary to provide care appropriate to the age of the patients served on his or her assigned unit.
- Demonstrated knowledge of the principles of life span growth and development and the ability to assess data regarding the patient's status and provide care as described in the department's policies and procedures manual.

Qualifications

Required:

- Graduate of an accredited college of pharmacy in the United States.
- Applications are accepted via PhORCAS until January 1st each year or as otherwise specified by the program director. University Hospitals & Clinics participates in the ASHP Resident Matching Program for the selection of residents into the program. Applications may be accepted in late March for any positions not filled during the matching process.

Required license(s):

- Current Pharmacist license in the State of Utah (obtain no later than September 30<sup>th</sup>.)

## **Appendix B**

### **PGY1 Required Competency Areas, Goals, and Objectives**

See the following section on the ASHP website for a variety of information related to the PGY1 Competency Areas

<https://www.ashp.org/Professional-Development/Residency-Information/Residency-Program-Directors/Residency-Accreditation/PGY1-Competency-Areas>

### **PGY2 Outcomes, Educational Goals and Objectives**

See the following section on the ASHP website for a variety of information related to the PGY2 Competency Areas

<https://www.ashp.org/Professional-Development/Residency-Information/Residency-Program-Directors/Residency-Accreditation/PGY2-Competency-Areas>

## **Appendix C**

PharmAcademic Instructions:

Log in to PharmAcademic at <https://www.pharmacademic.com/Login.aspx>  
and follow the Help and Support link

## **Appendix D**

### Service Commitment Record



Name:

Print Date:

| Required Shift Log Sheet |       |      |                          |       |      |                          |         |      |
|--------------------------|-------|------|--------------------------|-------|------|--------------------------|---------|------|
| Month                    | Shift | Date | Required                 | Shift | Date | ECS                      | PTO-S/U | Date |
| July                     |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
| August                   |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
| September                |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
| October                  |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
| November                 |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
| December                 |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
| January                  |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
| February                 |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
| March                    |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
| April                    |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
| May                      |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
| June                     |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |
|                          |       |      | <input type="checkbox"/> |       |      | <input type="checkbox"/> |         |      |

## Appendix E

### Past Resident Graduates and Project Titles

| Last Name | First Name | School        | Year                | Resident Project  |
|-----------|------------|---------------|---------------------|---|
| Athern    | Kathleen   | U of CO       | 17-18 (Int Med)     | Impact of Pregnancy on Antibiotic Clearance in Cystic Fibrosis Patients   |
| Barnicoat | Marie      | U of FL       | 17-18 (Informatics) | Development and Validation of a Computer Based Nomogram for Methotrexate Monitoring and Leucovorin Dose Adjustment  |
| Boyd      | Alexander  | Oregon State  | 17-18 (Track B)     | Implementation of enhanced pharmacy services (Comprehensive Medication Management) to improve prescribing rates of osteoporosis medications in women who had a fracture |
| Clark     | Breanna    | U of Kansas   | 17-18 (Track A)     | How much do our transplant patients really understand about their medications?  |
| Crockett  | Keaton     | UofU          | 17-18 (Track B)     | Pharmacist intervention to address antimicrobial stewardship in the primary care setting  |
| Fisher    | Jonathan   | MUSC          | 17-18 (Track A)     | The Pre and Post-assessment of the Impact of a Vancomycin Dosing Guideline for IV Drug Users  |
| Freeman   | Rachael    | U of Illinois | 17-18 (Track B)     | Impact of a Community Pharmacy Medication Synchronization Program on Adherence in an Academic Medical Center Patient Population   |
| Gaskill   | Eric       | MUSC          | 17-18 (Track A)     | PJP prophylaxis BPA improvement   |
| Gibson    | Amanda     | Jefferson CoP | 17-18 (ID)          | Impact of an electronic health record generated antibiotic timeout on antibiotic utilization and patient outcomes   |
| Griswold  | Cassia     | U of AZ       | 17-18 (Onc)         | Risk factors for VTE during chemotherapy in patients with bladder and testicular cancer   |
| Hayes     | Lisa       | U of TN       | 17-18 (Crit Care)   | Update of emergency department CA-MRSA antibiogram with review of antibiotic prescribing practices  |
| Jones     | Emma       | U of NE       | 17-18 (Onc)         | Analysis of various dosing strategies of capecitabine monotherapy for HER2-negative metastatic breast cancer  |
| Ku        | Jennifer   | UNC           | 17-18 (Track A)     | Implementation of a Neurocritical Care Unit Pain Management Guidance Document and its Impact on Nurse Satisfaction in Managing Pain in Neurocritical Care Patients      |
| Kurtti    | Amanda     | U of MN       | 17-18 (Onc)         | Levofloxacin prophylaxis in obese versus non-obese patients   |

| Last Name    | First Name | School         | Year              | Resident Project   |
|--------------|------------|----------------|-------------------|--|
| Larson       | Todd       | MUSC           | 17-18 (SoTx)      | Effectiveness of a renal sparing mTOR inhibitor based protocol in liver transplant recipients at a large academic medical center   |
| Lux          | Alexandria | U of Ohio      | 17-18 (Admin-1)   | Impact of a standardized method of processing prior authorizations at outpatient infusion clinics  |
| O'Brien      | M. Shea    | Drake          | 17-18 (Admin-1)   | Implementation of a new medication inventory management system and the effects on central pharmacy quality, performance and operations efficiency  |
| Pigott       | Heidi      | Duquesne U     | 17-18 (Am Care)   | Pharmacist intervention in patients with treatment resistant hypertension at an urban family medicine clinic   |
| Ratte        | Morgan     | U of RI        | 17-18 (Int Med)   | Treatment of Venous Thromboembolism in Cystic Fibrosis Patients  |
| Sandahl      | Tyler      | U of IA        | 17-18 (Onc)       | Examination of the Effect of Rituximab and Acetazolamide on Creatinine Elevation and Methotrexate Clearance in Patients Receiving High Dose Methotrexate                                   |
| Sherwood     | Sabrina    | Idaho State    | 17-18 (Track A)   | Development of an immunosuppression weaning protocol for kidney transplant recipients with allograft   |
| Steffens     | Laura      | UofU           | 17-18 (Crit Care) | Amiodarone Dosing in Obese Post-Cardiac Surgery Patients   |
| Trovato      | Anthony    | UofU           | 17-18 (Drug Info) | Preventing Transition Sticker Shock  |
| Wiederrich   | Jennifer   | UMKC           | 17-18 (Int Med)   | Evaluation of Nephrotoxicity in Cystic Fibrosis Patients treated with systemic Colistin for acute pulmonary exacerbation   |
| Allen        | Scott      | U of U         | 16-17 (Crit Care) | Evaluation of High-dose Ascorbic Acid in Thermal Injury  |
| Bertolaccini | Corinne    | Northeastern   | 16-17 (Crit Care) | Evaluation of anti-Xa levels in surgery patients receiving fixed dose heparin  |
| Biksacky     | Meryl      | U of U         | 16-17 (Track B)   | Implementation and evaluation of a clinical decision support tool to minimize drug-drug interactions among older patient populations in emergency department and ambulatory care settings. |
| Bliven       | Katie      | MUSC           | 16-17 (Onc)       | Utilization of granulocyte colony stimulating factors in metastatic solid tumors   |
| Bowden       | Ashley     | Ohio State     | 16-17 (Admin-2)   | Assessing the Impact of a Central Refill Center Using a Culture of Safety Survey   |
| Buss         | Brian      | U of Wisconsin | 16-17 (Infec Dis) | Impact of a Molecular Based Rapid Diagnostic for Bloodstream Infections with Antimicrobial Stewardship Notification at a National Cancer Institute   |
| Carey        | Jessica    | U of U         | 16-17 (Track A)   | Antineoplastic Policy Compliance among Clinical Pharmacists at an Academic Medical Center  |
| Carroll      | Emma       | U of Illinois  | 16-17 (Onc)       | Evaluation of Molecular Biomarkers and Response to Therapy in Prostate Cancer  |
| Copeland     | Vanessa    | Ohio State     | 16-17 (Onc)       | Outcomes evaluation for adult Ewing's, osteosarcoma, and rhabdomyosarcoma patients treated with off-label COG protocols  |

| Last Name | First Name | School            | Year              | Resident Project  |
|-----------|------------|-------------------|-------------------|---|
| Cotiguala | Laura      | Creighton         | 16-17 (SOTx)      | Evaluation of immediate versus delayed valganciclovir initiation for the prevention of cytomegalovirus in abdominal transplant recipients   |
| Cox       | Nicholas   | U of U            | 16-17 (Am Care)   | Retrospective analysis of pharmacist engagement with patients with non-cancer pain on chronic opioid therapy at a family medicine clinic  |
| Dwenger   | Andrew     | U of U            | 16-17 (Drug Info) | There was a policy for that? Implementing policies, guidelines, and formulary guidance into the electronic health record  |
| Ferreira  | Kristine   | Albany COP        | 16-17 (Int Med)   | Evaluation of Vancomycin Dosing and Nephrotoxicity in Intravenous Drug Users Admitted to the Internal Medicine Service  |
| Huynh     | Hoa        | U of U            | 16-17 (Int Med)   | Optimizing Pharmacokinetics and Pharmacodynamics of Intravenous Amikacin in Cystic Fibrosis Patients: Assessment of Clinical Outcomes and Nephrotoxicity  |
| Jones     | Emma       | U of Nebraska     | 16-17 (Track B)   | Implementation of inpatient chemotherapy education at an academic cancer center   |
| Kappenman | Ashley     | U of Iowa         | 16-17 (Admin-2)   | Designing and Implementing Centralized Mail Order Pharmacy Services: Phase 2  |
| Namanny   | Halee      | U of U            | 16-17 (Onc)       | Emergent inpatient anticancer therapy administration in patients with metastatic solid tumors   |
| Palasik   | Brittany   | U of Maryland     | 16-17 (Int Med)   | Evaluation of Single High-dose Oral Vitamin D3 Therapy versus Standard Care in Adult Cystic Fibrosis Patients   |
| Pan       | Irene      | U of U            | 16-17 (Track A)   | Incidence of Thrombosis Post-Kidney Transplant and the Use of Venous Thromboembolism Prophylaxis  |
| Pigott    | Heidi      | Duquesne          | 16-17 (Track B)   | Implementation and evaluation in opioid risk reduction strategies in a suburban family medicine clinic  |
| Ratte'    | Morgan     | U of Rhode Island | 16-17 (Track A)   | Review of methylprednisolone use for diffuse alveolar hemorrhage (DAH) in hematopoietic stem cell transplant (HSCT) recipients and the subsequent implementation of an evidence-based guideline |
| Steffens  | Laura      | U of U            | 16-17 (Track A)   | Minimizing the Delay in Time to Antibiotics in Patients Presenting to the Emergency Department with Urosepsis   |
| Trovato   | Anthony    | U of U            | 16-17 (Track A)   | Implementation of a medication reconciliation improvement bundle for acute care inpatients  |
| Black     | William    | U of KY           | 15-16 (Admin-2)   | Standardizing the Medication Reconciliation Process: Phase II   |
| Bliven    | Katherine  | MUSC              | 15-16             | Evaluating a change in surgical prophylaxis in kidney transplant recipients   |
| Bowden    | Ashley     | Ohio State        | 15-16 (Admin-1)   | AHRQ Community Pharmacy Survey on Patient Safety Culture: The results are in, what to implement now?  |
| Carroll   | Emma       | U of IL           | 15-16             | Effect of a Structured Pharmacist Education and Documentation Process on HCAHPS Pain Management Scores  |

| Last Name  | First Name | School    | Year            | Resident Project   |
|------------|------------|-----------|-----------------|--|
| Clough     | Alyson     | Purdue    | 15-16 (Onc)     | Characteristics of Long-Term Responders and Survivors of Metastatic Colorectal Cancer  |
| Coleman    | Abby       | Creighton | 15-16 (CC)      | Reducing pulmonary vasodilator dependence using oral sildenafil after coronary artery bypass grafting or valve procedure   |
| Cox        | Nicholas   | U of U    | 15-16           | Descriptive Analysis of Thrombophilia Testing in Hospitalized and Emergency Department Patients  |
| Ferreira   | Kristine   | Albany    | 15-16           | Improving pneumococcal vaccination rates of diabetic patients with use of a pharmacist workflow within a family medicine residency clinic                            |
| Garcia     | Breanne    | U of U    | 15-16 (Comm)    | Implementation of a pharmacy workflow process intended to improve Prevnar 13 immunization rates in patients 65 years and older                                       |
| Geurts     | Kelsee     | Roseman   | 15-16 (Comm)    | Evaluation of the use of statin therapy for primary prevention in type 2 diabetes patients between the ages of 40-75 years old: a retrospective, observational study |
| Harrington | Erik       | U of U    | 15-16 (Onc)     | Correlation of Genomic Aberrations and Response to First line VEGFR-TKI in Metastatic Renal Cell Carcinoma   |
| Hedges     | Ashley     | UNC       | 15-16 (CC)      | Retrospective Analysis of Levetiracetam Dosing in Neurosurgical Patients for Seizure Prophylaxis   |
| Holesh     | Lauren     | UNC       | 15-16 (Admin-2) | Health-System and Patient Care Benefits of a Centralized Prior Authorization Service: Phase II   |
| Hummert    | Shelly     | UofAZ     | 15-16 (Onc)     | Evaluation of safety and effectiveness of rivaroxaban compared to enoxaparin for treatment of venous thromboembolism in patients with malignancy                     |
| Huynh      | Hoa        | U of U    | 15-16           | Survey of audiology testing in cystic fibrosis patients who receive aminoglycosides for the treatment of acute pulmonary exacerbations                               |
| Kappenman  | Ashley     | U of IA   | 15-16 (Admin-1) | Designing and Implementing Centralized Mail Order Pharmacy Services  |
| Kelley     | Dawnyle    | U of SC   | 15-16 (IT)      | Pharmacist Evaluation of Fall-Risk via Use of a Medication Based Fall-Risk Assessment  |
| Prelewicz  | Stacy      | Wilkes    | 15-16 (Onc)     | FOLFOX relative dose intensity and correlation with survival outcomes in metastatic colorectal cancer  |
| Pugazhenth | Vidya      | U of CO   | 15-16 (IM)      | Survey of antibiotic utilization for treatment of Stenotrophomonas maltophilia infection in cystic fibrosis patients   |
| Smith      | Tonya      | MUSC      | 15-16 (IM)      | Pharmacokinetics of Intermittent Vancomycin in Adult Cystic Fibrosis Patients  |
| Traylor    | Katie      | UNC       | 15-16 (am care) | Aspirin Prescribing Practices for Primary Stroke Prevention in Elderly Women Following Monthly Population-Based Clinical Pharmacist Evaluation                       |
| Witt       | Benjamin   | Findlay   | 15-16 (DI)      | Development of a Method to Measure Adherence to Medication Management Policies   |

| Last Name      | First Name | School       | Year            | Resident Project  |
|----------------|------------|--------------|-----------------|---|
| Yeager         | Sarah      | Temple       | 15-16 (SOTx)    | Evaluation of the use of mTOR inhibitors in pancreas transplant recipients  |
| Arterbury      | Allison    | Arizona      | 14-15           | Evaluating Warfarin versus Aspirin for Post-operative VTE Prophylaxis in Patients with TKA and THA  |
| Au             | Trang      | Creighton    | 14-15 (onc)     | Evaluation of Safety and Effectiveness of Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors with Concomitant Proton Pump Inhibitors or Statins in Advanced Renal Cell Carcinoma |
| Babin          | Jennifer   | Alabama      | 14-15 (IM)      | Implementation of an Inpatient Computer-Based Inhaler Education Program   |
| Bailey         | Hanna      | Florida      | 14-15 (onc)     | Evaluation of neutropenic fever admissions in patients with solid tumors  |
| Black          | William    | Kentucky     | 14-15 (admin-1) | Standardizing the Medication Reconciliation Process   |
| Caffiero       | Nicole     | Wilkes U     | 14-15 (Comm)    | Interruptions and Distractions Before and After the Implementation of a Central Call Center on Pharmacists and Technicians in a Community Pharmacy Setting                                  |
| Coleman        | Abby       | Creighton    | 14-15           | Left Ventricular Assist Devices as Independent Risk Factors for GI Bleeding in Cardiovascular Surgery Patients  |
| Diamantopoulos | Anastasia  | TX Tech      | 14-15 (CC)      | Evaluation of the Efficacy and Safety of a Dexmedetomidine Protocol in Traumatic Brain Injury Patients  |
| Fung           | Brian      | Florida      | 14-15 (IT)      | Implementation of Antimicrobial Renal Dosing Decision Support in EPIC Using SmartText   |
| Hansen         | Alisyn     | Nebraska     | 14-15 (Am Care) | Implementation of Hypertension Shared Medical Appointments in An Academic Family Practice Clinic  |
| Holesh         | Lauren     | UNC          | 14-15 (admin-1) | Health-System and Patient Care Benefits of a Centralized Prior Authorization Service  |
| Hong           | Lisa       | Colorado     | 14-15 (IM)      | Pharmacokinetics of continuous infusion beta-lactams and tobramycin in the treatment of acute pulmonary exacerbations in adult cystic fibrosis patients                                     |
| Hoyt           | Jessica    | Wisconsin    | 14-15           | Analysis of Adherence to Asymptomatic Bacteriuria Treatment Guidelines for an Emergency Department at an Academic Medical Center  |
| Kosloske       | Ashley     | Minnesota    | 14-15           | Assessment of Empiric Antibiotic Prescribing Practices in the Emergency Department for Patients Admitted with a Diagnosis of Acute Pyelonephritis   |
| Louie          | Jessica    | Southern Cal | 14-15 (CC)      | A comparison of dexmedetomidine-propofol sedation to propofol sedation in mechanically ventilated patients  |
| Marini         | Erica      | Northeastern | 14-15 (admin-2) | Impact of Central Call Center on Distribution of Work Activities in Outpatient Pharmacies   |
| McPherson      | Jordan     | WVU          | 14-15 (onc)     | Predictors of Systemic Chemotherapy Utilization Within the Last 30 Days of Life   |
| Palmer         | Kelsey     | Montana      | 14-15 (Comm)    | Using failure mode and effects analysis (FMEA) methods to identify barriers contributing to low human papillomavirus  |

| Last Name      | First Name | School         | Year            | Resident Project  |
|----------------|------------|----------------|-----------------|---|
|                |            |                |                 | (HPV) vaccination rates in a University of Utah community-based clinic  |
| Schoen         | John       | Colorado       | 14-15           | Developing a Guideline for Weight-Based Dosing of Medications in Obese Adults   |
| Sirandas       | Bhanupriya | UI Chicago     | 14-15           | Evaluation of Induction Therapy in Renal Transplant Recipients  |
| Smith          | Tonya      | MUSC           | 14-15           | Survey of Antibiotic Utilization for Treatment of <i>Burkholderia cepacia complex</i> Infection in Cystic Fibrosis Patients       |
| Tanner         | Natalee    | Arizona        | 14-15 (onc)     | Utilization of Antineoplastic Chemotherapy Near the End-of-Life   |
| VanWagoner     | Eve        | Utah           | 14-15 (Comm)    | Patient Safety Culture within the University of Utah Health Care Community Pharmacies   |
| Burger         | Jordan     | Drake          | 13-14 (admin-2) | Strategizing Dispensing of Medications Prescribed in Specialty Clinics  |
| Diamantopoulos | Anastasia  | Texas Tech     | 13-14           | Risk of Venous Thromboembolism in Patients Receiving BID versus TID Prophylactic Heparin Dosing Based on a 90 kg Weight Cut-off   |
| Ford           | Ian        | UoPacific      | 13-14 (IT)      | The Effect of an Improved, Guideline-Based Clinical Decision Support Tool on Ambulatory Clinic Vaccination Rates                  |
| Fritz          | Kelly      | Ohio Northern  | 13-14 (onc)     | Evaluation of Complications of Chemotherapy in HIV-positive Patients on HAART Therapy Compared to HIV-negative Matched Controls   |
| Garza          | Carissa    | Incarnate Word | 13-14 (SoTX)    | Use and Outcomes of Rabbit Antithymocyte Globulin for Induction Therapy in Cardiac Transplantation: A Single Center Experience    |
| Hansen         | Alisyn     | Nebraska       | 13-14           | Evaluation of Aspirin Prescribing Practices in Elderly Women at the University of Utah Sugar House Health Center                  |
| Holcomb        | Kelly      | Auburn         | 13-14 (IM)      | Survey of Antibiotic Utilization for Treatment of <i>Mycobacterium abscessus</i> Infection in Cystic Fibrosis Patients            |
| Jacquez        | Machaela   | Utah           | 13-14 (Comm)    | The Identification of Medication Related Problems from a Medication Review Provided by clinical Pharmacist in a Community Setting |
| Johnston       | Kiersten   | Utah           | 13-14 (DI)      | Did we do What we Said we Would do? Developing a Process to Follow-up on P&T Decisions  |
| Liu            | Cindy      | Maryland       | 13-14 (Comm)    | Socio-economic and Clinical Characteristics of Patients Hospitalized with Prescription Opioid-Related Overdose                    |
| Louie          | Jessica    | Southern Cal   | 13-14           | Safety of Continuous Infusion Beta-lactam Antibiotics in Adult Cystic Fibrosis Patients During an Acute Pulmonary Exacerbation    |
| Marini         | Erica      | Northeastern   | 13-14 (admin-1) | Optimization of Care Transition practices Performed by Pharmacy Services Across a University Health System                        |
| Maxa           | Kim        | Drake          | 13-14 (onc)     | Voriconazole Safety in Obese and Non-Obese Patients   |
| McTish         | Ryan       | Georgia        | 13-14 (CC)      | Experience with Colistin in the Management of an Extensive Drug Resistant Acinetobacter Outbreak in an ICU                        |



| Last Name | First Name  | School           | Year            | Resident Project   |
|-----------|-------------|------------------|-----------------|--|
| Miles     | A. Meredith | Georgia          | 13-14 (Comm)    | The Gap in Transitions of Care in Heart Failure Patients: When, Why and Who do Drug-related Problems Affect?   |
| Paul      | Shilpa      | Illinois-Chicago | 13-14 (onc)     | Utilization of Antineoplastic Chemotherapy Near the End-of-Life  |
| Ratermann | Kelley      | Kentucky         | 13-14           | Effect of Pharmacy-Initiated Chronic Pain Management Admission Notes on HCAHPS Scores  |
| Schoen    | John        | Colorado         | 13-14           | Descriptive Case-series of the Use of Kcentra™ for the Reversal of Warfarin-associated Major Bleeding  |
| Thompson  | Johanna     | Washington       | 13-14 (Am Care) | A Clinical pharmacist's Assessment of Bisphosphonate Use for Osteoporosis and Appropriateness of Long Term Therapy   |
| Wilds     | Brandon     | LECOM            | 13-14 (onc)     | Clinical Outcomes and Risk Factors for Treatment Failure and Recurrence of <i>Clostridium difficile</i> Infections in Hematopoietic Stem Cell Transplant Patients  |
| Wolfe     | Brianne     | Montana          | 13-14 (CC)      | 'Development and Implementation of a Protocol for the Treatment of Acute Massive Pulmonary Embolism  |
| Bhakta    | Zubin       | TX Tech          | 12-13 (Int Med) | A Survey of the Pharmacist's Role at U.S. Cystic Fibrosis Foundation - Accredited Centers  |
| Bowles    | Harmony     | New Mexico       | 12-13 (onc)     | Incidence of febrile neutropenia in patients with HER2 positive breast cancer receiving docetaxel, carboplatin, and trastuzumab (TCH) for adjuvant treatment   |
| Burger    | Jordan      | Drake            | 12-13 (admin-1) | Verification of benefits for clinic and infusion medication administration   |
| Buu       | Jenni       | Idaho State U    | 12-13 (comm)    | Improving evidence-based guideline implementation – Identifying barriers and developing a process to improve adult influenza vaccination rates and clinical guideline implementation in a community clinic setting |
| Ford      | Ian         | UoPacific        | 12-13           | Effect of Implementation of a Barcode Medication Administration System In the Incidence of Medication Administration Errors  |
| Fritz     | Kelly       | Ohio Northern    | 12-13           | Analysis of Community-Oriented Resistance Patterns in Urinary Tract Infections for an Emergency Department at an Academic Medical Center   |
| Gillespie | Matthew     | Michigan         | 12-13 (TX)      | Cytomegalovirus prophylaxis with valganciclovir in kidney transplant recipients: A single-center experience  |
| Hays      | Emily       | Nebraska         | 12-13 (Am Care) | Pharmacist intervention to decrease risk of hypoglycemia in older patients with diabetes mellitus  |
| Holsopple | Megan       | Creighton        | 12-13 (DI)      | How SMART can we be? – Maximizing the use of smart pump infusion data to improve guardrail programming   |
| Johnston  | Kiersten    | Utah             | 12-13           | One-Stop Shopping: Integrating Medication Use Information into the Online Formulary at the University of Utah Hospitals and Clinics  |



| Last Name  | First Name | School        | Year            | Resident Project   |
|------------|------------|---------------|-----------------|--|
| McTish     | Ryan       | Georgia       | 12-13           | Observational Study of a High Dose Heparin Protocol with Bolus in Comparison to a Bolus-free Low Dose Heparin Protocol in Brain Injured Patients with Concomitant Thrombosis |
| Mishra     | Adya       | Utah          | 12-13           | Evaluation of acute coronary syndrome/myocardial infarction (ACS/MI) heparin drip protocols in obese patients at the University of Utah Hospital                             |
| Nguyen     | Truong     | UMKC          | 12-13 (IT)      | Implementing Clinical Decision Support - Medication Dosing in Renal Impairment   |
| Ogborn     | Diane      | Utah          | 12-13 (comm)    | Tdap Vaccination Rates in Pregnant Women through Electronic Medical Record Process Changes   |
| Parikh     | Kinjal     | UNC           | 12-13 (onc)     | Outcomes of Metastatic Renal Cell Carcinoma Patients with Favorable Clinical and Histologic Features Treated with High-Dose Interleukin-2 Therapy                            |
| Pecoraro   | Joshua     | Wyoming       | 12-13 (onc)     | Effect of thrombocytosis on venous thromboembolism risk in pancreatic cancer patients receiving chemotherapy   |
| Rim        | Matthew    | Western U     | 12-13 (admin-2) | Developing a Pharmacy Benefit Management Program (Part II)   |
| Sledge     | Tyler      | TX Tech       | 12-13 (CC)      | Measuring the clinical impact of surgical intensive care pharmacists using documentation in the electronic medical record  |
| Bailey     | Erin       | West Virginia | 11-12 (onc)     | Opportunity to Optimize Oral Chemotherapy Outcomes: The Pharmacist's Role  |
| Bhakta     | Zubin      | TX Tech       | 11-12           | Evaluation of Prasugrel vs. High-Dose Clopidogrel in Acute Coronary Syndrome Patients  |
| Burgeson   | Mick       | Colorado      | 11-12 (IT)      | Developing a Web-Based Collaborative Information Sharing Environment   |
| Cline      | Kyle       | UMKC          | 11-12           | Comparison of the Treatment and Prophylaxis of Patients with Heparin-Induced Thrombocytopenia Prior to and Following Hospital Guideline Implementation                       |
| Ghaffarian | Sanaz      | UCSF          | 11-12 (DI)      | Reformulating the Formulary at the University of Utah Hospitals and Clinics  |
| Hiller     | Sara       | UMKC          | 11-12 (onc)     | Evaluation of Iron Deficiency Anemia and Treatment in Cancer Patients  |
| Parikh     | Kinjal     | UNC           | 11-12           | Use of Simvastatin in Transplant Patients and the Incidence of Side Effects, and Evaluation of Efficacy  |
| Rim        | Matthew    | Western U     | 11-12 (admin)   | Developing a Pharmacy Benefit Management Program   |
| Robinson   | McKay      | Wyoming       | 11-12 (comm)    | Bridging the Gap Between FDA Safety Warnings and Patients: Are Pharmacists the Appropriate Messengers?   |
| Sledge     | Tyler      | TX Tech       | 11-12           | Evaluation of a New Hyperglycemia Protocol Across Multiple Intensive Care Units  |
| Soni       | Nimisha    | Wayne State   | 11-12 (TX)      | Analysis of Risk Factors for the Development of Chronic Kidney Disease After Orthotopic Liver Transplant   |
| Sorensen   | Teshia     | Wyoming       | 11-12           | Development of Albumin Use Guidelines  |

| Last Name     | First Name | School         | Year          | Resident Project   |
|---------------|------------|----------------|---------------|--|
| Streeter      | Jessica    | New Mexico     | 11-12 (onc)   | Hematologic Effects of Sulfamethoxazole/Trimethoprim and Dapsone for Pneumocystis jiroveci Pneumonia Prophylaxis in Patients with Glioblastoma Multiforme Receiving Concomitant Temozolomide and Radiation |
| White         | Jacob      | Utah           | 11-12 (CC)    | Evaluation of Administration Rate of 23.4% Sodium Chloride on Duration of Intracranial Pressure Control  |
| Bailey        | Erin       | West Virginia  | 10-11         | Clinical outcomes of MRSA bacteremia treated with vancomycin: Assessing the utility of vancomycin trough serum concentrations and AUC <sub>24</sub> /MIC   |
| Carlson       | Adrian     | South Carolina | 10-11 (TX)    | Analysis of Rabbit Antithymocyte Globulin Induction Therapy in Elderly Kidney Transplant Patients  |
| Filtz         | Michael    | Maryland       | 10-11 (onc)   | Feasibility, Justification and Clinical Development of a Hospice Care Program  |
| Gebarski      | Matt       | U Michigan     | 10-11 (IT)    | A Comparison of Medication Order Error Rates in a Neonatal Intensive Care Unit Before and After Computerized Prescriber Order Entry Implementation   |
| Ghaffarian    | Sanaz      | UCSF           | 10-11         | Antiplatelet Therapy Versus Anticoagulation in Patients with Cervical Artery Dissection  |
| Giouroukakis  | Mary       | New York       | 10-11 (DI)    | Descriptive Case-Series of the Treatment and Prophylaxis of Patients with HIT at University of Utah Hospital   |
| Hatch         | Heather    | Utah           | 10-11         | Evaluation of Adherence to Thienopyridines After Discharge from University of Utah Hospital Cardiovascular Medicine Unit   |
| Katzourakis   | Michael    | Utah           | 10-11 (admin) | Impact of CPOE decision support on IV to PO medication interchange initiative: Assessing quality and cost  |
| Hiller        | Sara       | UMKC           | 10-11         | Evaluation of Peri-procedural Anticoagulation in Patients Undergoing Atrial Fibrillation Ablation  |
| Prazak        | Ann Marie  | Houston        | 10-11 (CC)    | Evaluation of the Efficacy and Safety of a Dexmedetomidine Protocol  |
| Stenehjem     | David      | Minnesota      | 10-11 (onc)   | Factors affecting clinical response to tyrosine kinase inhibitors in chronic myeloid leukemia  |
| Votroubek     | Nathan     | U Iowa         | 10-11         | What are the Underlying Causes of Resistance to Erythropoiesis Stimulating Agents?   |
| Williams      | Kali       | Wisconsin      | 10-11 (onc)   | Clinical outcomes of rasburicase administration in tumor lysis syndrome: A retrospective cohort study  |
| Alwan         | Michael    | Butler         | 09-10 (admin) | Evaluation of workflow before and after implementation of computerized provider order entry (post-implementation)  |
| Filtz         | Michael    | Maryland       | 09-10         | Evaluation of 14.6% NaCl for the Treatment of Increased Intracranial Pressure in Traumatic Brain Injury  |
| Mahmoudjafari | Zahra      | Missouri       | 09-10 (onc)   | Correlating electrolyte abnormalities with hematopoietic recovery following myelosuppressive chemotherapy  |
| MacDonald     | Elyse      | Creighton      | 09-10 (DI)    | Drug Shortages Impact on Patient Safety  |

| Last Name | First Name | School        | Year          | Resident Project  |
|-----------|------------|---------------|---------------|---|
| Miars     | Laura      | Butler        | 09-10 (onc)   | Comparative toxicities of 2 high-dose IL-2 treatment doses at Huntsman Cancer Hospital  |
| Milne     | Nikki      | Utah          | 09-10         | Evaluation of the Appropriateness of Bisphosphonate Therapy Using the FRAX Calculator   |
| Prazak    | Ann Marie  | Houston       | 09-10         | Evaluation of the cardiothoracic surgery heparin protocol at the University of Utah Hospital  |
| Simons    | Heidi      | Montana       | 09-10 (CC)    | Evaluation of Cardiac Arrest Documentation in an Academic Teaching Hospital with Pilot Implementation of Electronic Cardiac Arrest Documentation                              |
| Stenehjem | David      | Minnesota     | 09-10         | Effects of P-glycoprotein Modulators on Acute Epileptic Events  |
| Wagstaff  | Dustin     | USN           | 09-10 (CC)    | Surgical ICU Nurse-Owned Wake-up, Extubate and Discharge: (SNOWED) Trial  |
| Williams  | Kali       | Wisconsin     | 09-10         | A Retrospective Dose-finding Study of Hydroxyurea for Leukocytoreduction in Myelogenous Leukemia  |
| Alwan     | Michael    | Butler        | 08-09 (admin) | Evaluation of workflow before and after implementation of computerized provider order entry (pre-implementation)  |
| Burt      | Lauren     | U Florida     | 08-09 (onc)   | Vitamin Deficiencies in Anemic Cancer Patients  |
| Dryer     | Megan      | Utah          | 08-09         | Medication Use Evaluation of Intravenous Acyclovir for Suspected Viral Encephalitis   |
| Kenyon    | Nicole     | Midwestern IL | 08-09 (TX)    | Evaluation of a transplant specialty pharmacy service line on renal allograft function and survival   |
| Mason     | Russell    | UC San Diego  | 08-09         | Visual Compatibility of Intravenous 3% Hypertonic Saline  |
| Myers     | Kathryn    | U Conn        | 08-09 (CC)    | Hospital-wide Evaluation of Off-Label Use of Recombinant Activated Factor VII   |
| Ngo       | Nolan      | U of Iowa     | 08-09 (onc)   | Efficacy Assessment of Current Antiemetic Regimens for Chemotherapy-Induced Nausea and Vomiting at the Huntsman Cancer Institute  |
| Simons    | Heidi      | Montana       | 08-09         | Implementation of an Enoxaparin Dosing Protocol for Venous Thromboembolism Prophylaxis in Obese Surgical Intensive Care Unit Patients   |
| Walker    | Amanda     | Kansas        | 08-09         | Evaluation of Combined Warfarin and Antiplatelet Use at the University of Utah Thrombosis Center and Community Clinics  |
| Walraven  | Carla      | New Mexico    | 08-09         | Evaluation of the diagnostic and therapeutic management of CA-MRSA SSTIs in the emergency department  |
| Winslow   | Roger      | USN (NV)      | 08-09 (admin) | Breakeven Analysis of a Proposed Pharmacy Discharge Prescription Medication Reconciliation Program  |
| Lin       | Hsin       | Northeastern  | 07-08 (CC)    | The Early Use of Intravenous Neostigmine for the Prevention of Barbiturate-induced Ileus and Necessity for Parenteral Nutrition in Neurosurgical Patients in Barbiturate Coma |
| Gallegos  | Amanda     | Utah          | 07-08         | Cystic Fibrosis Quality Improvement Study   |

| Last Name    | First Name | School         | Year          | Resident Project   |
|--------------|------------|----------------|---------------|--|
| Truax        | Crystal    | Drake          | 07-08 (TX)    | Impact of reduced-dose mycophenolic acid therapy on the incidence of renal transplant rejection and graft loss in corticosteroid withdrawal patients                           |
| Shipley      | R. Wayne   | Creighton U    | 07-08 (CC)    | A Monte Carlo Simulation of Piperacillin-Tazobactam in Critically Ill Patients with Pseudomonas Aeruginosa   |
| Myers        | Kathryn    | U Conn         | 07-08         | Electrolyte Replacement Protocol Design and Assessment in the ICU Setting  |
| Miles        | LeeAnn     | Utah           | 07-08         | Comparison of Indomethacin and Ibuprofen in Neonates with Patent Ductus Arteriosus   |
| VanDemark    | Kimberly   | Wisconsin      | 07-08         | Conversion of chronic hemodialysis patients from intravenous erythropoietin alfa to intravenous darbepoetin alfa   |
| Ponce        | Paola      | Kansas         | 07-08         | Establishing Optimal Dosing of Intravenous Amiodarone in the Treatment of New Onset Atrial Fibrillation for Postoperative Surgical Patients                                    |
| Sanders      | Stephanie  | Ferris State U | 07-08 (Onc)   | Establishing and Outpatient Anticoagulation Clinic for Oncology Patients   |
| Lampas       | Mary       | Purdue         | 07-08 (Onc)   | Assessment of Appropriate Vancomycin Use in Neutropenic Patients   |
| Sanders      | Tom        | Ferris State U | 07-08 (DI)    | Building a Better Drug Budgeting System: A Survey and Assessment   |
| Winslow      | Roger      | USN (NV)       | 07-08 (admin) | The Financial Impact of Pharmacy Specialty Billing Services  |
| Au           | Cam        | Utah           | 06-07         | Insulin availability in a parenteral nutrition solution  |
| Au           | Lara       | Utah           | 06-07 (Onc)   | Analysis of anticoagulation practices in multiple myeloma patients treated with thalidomide and dexamethasone  |
| Canann       | David      | Midwestern AZ  | 06-07         | Drug compatibility during Y-site infusions   |
| Condie       | Chad       | Utah           | 06-07         | Drug compatibility during Y-site infusions   |
| Dang         | Kim        | Utah           | 06-07 (CC)    | Levothyroxine infusions in the setting of shock and its effects on hemodynamic stability   |
| Draper       | Leslie     | Utah           | 06-07         | Venous thromboembolism prevention in the morbidly obese medically ill patient: A pharmacological analysis of the predictability of prophylactic weight-based enoxaparin dosing |
| Kantesaria   | Pranish    | Massachusetts  | 06-07 (admin) | Improved patient outcomes in a pharmacist managed anemia clinical at Huntsman Cancer Hospital  |
| Lingenfelter | Erin       | Ohio Northern  | 06-07 (CC)    | The management of sepsis and septic shock in the SICU of the University of Utah Hospitals and Clinics  |
| Masck        | Mary       | Purdue         | 06-07         | The role of D-ribose in patients diagnosed with fibromyalgia   |
| Truax        | Crystal    | Drake          | 06-07         | Evaluation of the drug interaction between low-dose fluconazole and tacrolimus in renal transplant patients  |
| Brooks       | Tyson      | Wyoming        | 05-06 (IM)    | Exacerbation rates associated with non-selective vs. B1 selective beta-blocker use in patients with asthma or chronic obstructive pulmonary disease                            |

| Last Name  | First Name | School        | Year        | Resident Project  |
|------------|------------|---------------|-------------|---|
| Burns      | Shauna     | Mercer        | 05-06 (Onc) | Impact of cytokine prophylaxis on patients receiving moderately myelosuppressive chemotherapy regimens  |
| Dang       | Cathyen    | Utah          | 05-06 (CC)  | Intensive insulin therapy in critically ill surgical patients: evaluation of outcome benefit of tighter glucose control   |
| Gilreath   | Jeffrey    | Wisconsin     | 05-06       | Developing a collaborative practice agreement between pharmacists and oncologists to manage erythropoietic growth factor therapy for oncology patients in a pharmacist run ambulatory oncology center |
| Ho         | Mei-Jen    | Rutgers U     | 05-06 (IT)  | Economic benefits of self-managed pharmacy benefit manager in a large academic hospital   |
| Kantesaria | Pranish    | Massachusetts | 05-06       | Retrospective analysis of Cinacalcet use in renal transplant patients at an academic medical center   |
| Nighorn    | Katie      | Wisconsin     | 05-06       | Efficacy of a pharmacist managed hypertension service   |
| Roberts    | Keri       | Northeastern  | 05-06 (TX)  | Impact of a rapid steroid withdrawal protocol on height and weight outcomes in pediatric renal transplant recipients  |
| Sederholm  | Benson     | Utah          | 05-06       | Pharmacist managed hyperlipidemia care versus usual care for patients with dyslipidemia in a UUHCS community clinic setting   |
| Smith      | Lara       | Utah          | 05-06       | Evaluation of venous thromboembolism prophylaxis in medically ill oncology patients   |
| Allard     | Jill       | Nebraska      | 04-05       | Retrospective Review of Steroid Withdrawal in Renal Transplant Patients   |
| Howarth    | Shannon    | UNC           | 04-05       | Improving Immunization Rates for Inpatients at UUHC   |
| Neyens     | Ron        | So Dakota     | 04-05       | Intensive Insulin Therapy in Burn Trauma Patients   |
| Puett      | Heather    | UNC           | 04-05       | Workplace Contamination with Antineoplastic Agents in a new Cancer Hospital Using a Closed Drug preparation System  |
| Wohlt      | Paul       | Wisconsin     | 04-05       | Outpatient Management Protocol for Venous Thromboembolic Disease  |
| Bohm       | Nicole     | Florida       | 04-05 (IM)  | Appropriateness of Fluoroquinolones as Empiric Therapy for Nosocomial UTIs  |
| Ludwig     | Kyle       | St. Louis CoP | 04-05 (CC)  | Ventilator-Associated Pneumonia: A Retrospective Look at the Pharmacological Management in the SICU   |
| Mills      | Kyle       | Wyoming       | 04-05 (IM)  | Asthma Medications and their association with Symptomatic Gastroesophagels Reflux   |
| Wilkinson  | Joey       | Wyoming       | 04-05 (Tx)  | Retrospective Review of BK Nephropathy in a Renal Transplant Population   |
| Aggers     | Patricia   | Idaho State   | 03-04       | Review of Efficacy and Safety of Valganciclovir for CMV Prophylaxis in Adult Renal Transplant Recipients  |
| Beaumont   | Cody       | Michigan      | 03-04       | Investigation of the Venous Thromboembolism (VTE) Prophylaxis in Patients at our Rehabilitation Unit  |

| Last Name   | First Name | School         | Year       | Resident Project  |
|-------------|------------|----------------|------------|---|
| Buchanan    | Christie   | PCP            | 03-04(Tx)  | Assessing the pharmacokinetics of MMF by bound and free levels of MPA and MPAG in Renal Failure   |
| Christensen | Russell    | Utah           | 03-04 (IM) | The Predictability of Antibiotic Sensitivities Based on the Urine Analysis Nitrite Test   |
| Gebhart     | Benjamin   | Drake          | 03-04 (CC) | Sedation Management in a Surgical Intensive Care Unit   |
| Hermansen   | Erica      | Utah           | 03-04 (PC) | Evaluation of pharmacist vs physician anticoagulation management in a family medicine residency clinic  |
| Jefferies   | Kristen    | Utah           | 03-04      | The Impact of a Pharmacist initiated medication History on Patient Satisfaction and Accuracy of Medications Ordered                                 |
| Kay         | Brent      | Utah           | 03-04      | Evaluation of Medication Ordering for University Hospital   |
| Wilkinson   | Joey       | Wyoming        | 03-04      | Describing the Usage Patterns, Reimbursement Rates, Acquisition Costs and Efficacy of Epoetin alfa and Darbepoetin at the Huntsman Cancer Institute |
| Dell        | Kamila     | UNC            | 02-03 (CC) | Medication propensity to clog nasoduodenal feeding tubes  |
| Feddema     | Sarah      | U of Wyoming   | 02-03 (DI) | Evaluating Online Formulary Vendors for a University Hospital   |
| Gebhart     | Benjamin   | Drake          | 02-03      | Glucose control using a standardized sliding scale insulin protocol in a surgical intensive care unit   |
| McDevitt    | Lisa       | Nebraska       | 02-03 (Tx) | Evaluating the Benefit of aggressive anemia treatment in renal transplant patients  |
| Scott       | Amy M      | Idaho State    | 02-03      | Inpatient utilization of erythropoietin and darbepoetin: improving treatment of anemia  |
| Skordos     | LeAnne     | Utah           | 02-03      | Evaluation of the Venous Thromboembolism prophylaxis in medical patients  |
| Strain      | Joe        | South Dakota   | 02-03      | Health Care Screening at University Hockey Games  |
| VanBeuge    | Derrick    | Idaho State    | 02-03      | Retrospective Analysis of anemia and associated cardiovascular and renal allograft complications post primary renal transplant                      |
| Dell        | Kamila     | UNC            | 01-02      | Evaluation of a Heparin Nomogram  |
| Fakata      | Keri       | Nebraska       | 01-02      | Sirolimus inhibitions of P-Glycoprotein: a Possible Mechanism for increased Nephrotoxicity with concomitant use with Cyclosporine                   |
| Feddema     | Sarah      | U of Wyoming   | 01-02      | Physical Compatibility of Vasopressin with Commonly Used Medications in Cardiac Arrest  |
| Moaleji     | Norwan     | Colorado       | 01-02      | Assessment of Cholesterol Treatment in a Family Medicine Clinic: Are we at goal with NCEPIII  |
| Peterson    | Dave       | Utah           | 01-02 (DI) | Improving Documentation During Codes: A Process Improvement Project   |
| Sundberg    | Aimee      | U of Wisconsin | 01-02 (Tx) | Opinions of Pediatric Renal Transplant Patients about Switching from Cyclosporine to Tacrolimus   |
| Wick        | Catherine  | U Washington   | 01-02      | Evaluation of Surface and Personnel Cytotoxic Contamination at the Huntsman Cancer Institute  |



| Last Name | First Name | School               | Year       | Resident Project   |
|-----------|------------|----------------------|------------|--|
| Carter    | Orly       | U of Utah            | 00-01 (PC) | A Multidisciplinary Approach to Hypertension Management: Utilizing a Pharmacist as an Education Provider in a Family Medicine Clinic                   |
| Chalverus | Carrie     | U Washington         | 00-01      | Surfactant Adverse Outcomes Monitor: A Comparison of Infasurf vs. Survanta   |
| Crompton  | Jason      | Philadelphia         | 00-01 (Tx) | Impact of Basiliximab Induction Therapy in Adult Living Renal Transplants  |
| Dalpiaz   | Anthony    | U of Montana         | 00-01 (DI) | Outcome Evaluation of Combination High Dose Daily interferon Alfa Plus Ribavirin in Patients with Hepatitis C  |
| Davis     | Lynn       | U of Florida         | 00-01      | Estimation of Creatinine Clearance between Aminoglycoside Pharmacokinetics, Cockcroft-Gault, and Jelliffe Methods in Critically Ill Patients           |
| Sundberg  | Aimee      | U of Wisconsin       | 00-01      | Opinions of Pediatric Renal Transplant Patients about Switching from Cyclosporine to Tacrolimus  |
| Crompton  | Jason      | Philadelphia         | 99-00      | Development of a Fail-Safe Medication Error Prevention System in Cancer Chemotherapy   |
| Dalpiaz   | Anthony    | U of Montana         | 99-00      | Treatment of Myofascial Trigger Point Pain with Topical Lidocaine Patches  |
| Fox       | Erin       | U of Utah            | 99-00 (DI) | Assessing the Cost Savings of a Pharmacy-Administered IV to PO Interchange Program   |
| Johnson   | Stephanie  | Creighton U          | 99-00      | Assessing the Impact of Switching Maintenance Immunosuppression from Cyclosporine to Tacrolimus in Pediatric Renal Transplant Patients                 |
| McGee     | Kelly      | U of Cincinnati      | 99-00 (PC) | Homocysteine Reduction in a Geriatric Clinic Population: Effectiveness of Multivitamin Supplements   |
| Raap      | Jonathon   | U of Texas at Austin | 99-00      | Movement Toward Becoming an Integrated Health Delivery System: Initiation of Pharmacy Services in a Primary Care Clinic                                |
| Grahmann  | Paula      | Texas at Austin      | 98-9       | Analysis of Pain Clinicians' Perceptions of Opioid Use in Chronic Non-malignant Pain   |
| Martin    | Andrew     | Ferris State U       | 98-9 (DI)  | Developing a Drug Evaluation Process   |
| Panjwani  | Nooruddin  | Texas at Austin      | 98-9       | Treatment of Post-Ictal Vascular headaches with Intra-Nasal Sumatriptan (Imitrex)  |
| Smith     | Lonnie     | Tennessee            | 98-9       | Prophylactic Low Dose Fluconazole after Primary Renal Transplantation  |
| Voytilla  | Krista     | U of Pittsburgh      | 98-9       | Compatibility of Dolasetron with Commonly Used Post-Surgical Drugs During Y-Site Delivery  |
| Wellman   | Melinda    | Utah                 | 98-9 (PC)  | Assessing Medication prescribing Appropriateness, Patient Educational Needs and Compliance in Ambulatory Family Medicine Patients: A Descriptive Study |
| Bearden   | David      | U of Illinois        | 97-8       | Evaluation of Amiloride Use with Amphotericin B in the Oncology Patient  |
| Mathiason | Mark       | Creighton            | 97-8       | A Three Year Retrospective Survey of Yeast Isolates Compared to Fluconazole Use in a University Hospital   |
| Nguyen    | Long       | Houston              | 97-8       | Evaluation of Patient's Satisfaction Utilizing Telepharmacy to Deliver Pharmaceutical Care   |

| Last Name         | First Name | School         | Year       | Resident Project  |
|-------------------|------------|----------------|------------|---|
| Phillips          | Mark       | Idaho State    | 97-8       | An Assessment of Hyperlipidemia in HIV Patients Treated with Protease Inhibitors  |
| Wetzstein         | Gene       | N.Dakota State | 97-8       | The Impact of a Clinical Event Management System on Pharmacy Services in a University Medical Center  |
| Brumfield         | Lauren     | MCV            | 96-7       | Effect of Administration Sets and Volumes on the Delivery of Gentamicin to Low-Birth-Weight Infants   |
| Salverson         | Sandra     | U of Illinois  | 96-7       | Using Telemedicine as a Tool to Implement Pharmaceutical Care in Remote Ambulatory Setting  |
| Mullin            | Shantel    | Idaho State U  | 96-7 (DI)  | Computerizing Drug Information Services- External Survey and Internal Evaluation  |
| Shah              | Hetal      | Rutgers U      | 96-7       | Assessment of Clinical Outcomes Utilizing Predicted Carboplatin AUC in Autologous Bone Marrow Transplant (ABMT) Patients Treated with a Stamp V Regimen |
| Vaezi             | Liza       | Creighton U    | 96-7       | Application of a Multi-Attribute Utility Theory (MAUT) Model to Select Agents for Use in ICU Sedation   |
| Hutchings         | Steven     | Idaho State U  | 95-6       | Y-Site Physical Compatibility of Cefmetazole with Other Commonly Used Drugs   |
| Johnson           | Melissa    | St Louis U     | 95-6       | Evaluation of Current Serotonin Antagonist Use in Chemotherapy Treated Patients   |
| Mullin            | Shantel    | Idaho State U  | 95-6       | Assessing the Use of an Emesis Questionnaire for Monitoring Chemotherapy and Antiemetic Outcomes in Ambulatory Oncology Patients                        |
| Rubingh           | Carla      | U of Nebraska  | 95-6       | Therapeutic Interchange by Pharmacists: Outcomes in an Ambulatory Care Clinic   |
| Albright          | Lisa       | U of Nebraska  | 94-5       | Evaluating Inpatient and Outpatient Allergy Documentation in a University Hospital Setting  |
| Cerveney          | Joli       | U of Nebraska  | 94-5 (HIV) | Using Pharmaceutical Manufacturer Support to Fund an HIV Residency Program at University Hospital   |
| Furniss           | Shawn      | Idaho State U  | 94-5       | Indomethacin vs Surgical Ligation for the Treatment of Patent Ductus Arteriosus- A Retrospective Chart Review   |
| Loeffelbein       | Robert     | U of Nebraska  | 94-5       | A Comparison of Parenteral Nutrition Solution Osmolarity and Loss of Peripheral Venous Access in Neonates   |
| Muncey            | Lance      | Idaho State U  | 94-5       | Implementation and Evaluation of New American Diabetes Association Standards of Care for the Diabetic Patients in a Family Practice Clinic              |
| Portley           | Bonnie     | Idaho State U  | 94-5       | The Effect of Osmolality on Feeding Tolerance in the Preterm Neonate  |
| Andrews-Boudreaux | Stacey     | Idaho State U  | 93-4       | Evaluation of Depression in the Elderly Using the Geriatric Depression Scale  |
| Cerveney          | Joli       | U of Nebraska  | 93-4       | Evaluation of a Pharmacist's Role During Cardiac Arrest   |
| DiGregorio        | Vicky      | UC SF          | 93-4       | Evaluating the Accuracy of Medical and Drug Histories in Russian Patients' Charts- An Evaluative Study  |
| Grunden           | John       | U of Utah      | 93-4 (DI)  | Evaluation of an Electronic Formulary   |



| Last Name | First Name | School           | Year      | Resident Project   |
|-----------|------------|------------------|-----------|--|
| Najari    | Zohre      | U of Arizona     | 93-4      | Y Site Physical Compatibility of Common BMT Drug Combos  |
| Beckwith  | Christina  | U of Utah        | 92-3 (DI) | Surveying Former Drug Information Residents for Career Aspirations   |
| Cafee     | Anne       | U of Florida     | 92-3      | Pharmacist Counseling when a Sample Medication is Dispensed  |
| Davis     | Gary       | U of Arizona     | 92-3      | Evaluation of Transdermal Nicotine Replacement Therapy in the Outpatient Population - an Evaluative Study  |
| Kelsey    | Julie      | U of the Pacific | 92-3      | First Dose Gentamicin Pharmacokinetics in Obstetric Patients   |
| Moser     | Lynette    | U of Illinois    | 92-3      | Pharmacist Participation in an Established Hyperlipidemia Clinic- A Descriptive Report   |
| Dwinell   | Andrea     | U of Minnesota   | 91-2      | Patient Compliance with Prescription Filling After Discharge from the Emergency Department   |
| Robinette | Bryan      | Tennessee        | 91-2      | Physical Compatibility of Ceftazidime Sodium, and Methylprednisolone Sodium Succinate with Secondary Intravenous Agents via Simulated Y-Site Injection |